PPARD and cardiac arrhythmia: Consistently, administration of GW0742 resulted in a concomitant reduction in overall arrhythmia severity in the hearts of treated animals (Figure 1C) compared with that in the untreated ones (total number of reperfusion-induced ES 161.4 ± 46.7 for the Control group compared with 43 ± 4 for the GW group), which was attenuated in the presence of the PPARβ/δ antagonist (ES 178.3 ± 43.3 for the GSK/GW group).